Sun Pharma to Acquire Organon for $14 Per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Catch up on the weekend's top five stories with this list compiled by The Fly: 1) President Trump said on social media: "I just cancelled the trip of my representatives going is Islamabad, Pakistan, to meet with the Iranians. Too much time wasted on traveling, too much work! Besides which, there is tremendous infighting and confusion within their 'leadership.' Nobody knows who is in charge, including them. Also, we have all the cards, they have none! If they want to talk, all they have to do is call!!!" 2) Sun Pharmaceutical Industries and Organon & Co. (OGN) announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75B. Transaction Summary: Sun Pharma will acquire 100% of Organon's issued and outstanding shares for cash. Sun Pharma plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The transaction will be effected by a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. The transaction is expected to close in early 2027, subject to customary conditions, including regulatory approvals and Organon stockholder approval. The transaction has been approved by the Boards of Directors of both Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders. 3) Oracle's (ORCL) $16B financing for a giant data center in Michigan has finally wrapped after months of negotiations with investors, Davide Barbuscia, Caleb Mutua, and Natalie Wong of Bloomberg reports. Bank of America (BAC) sold $14B of bonds tied to the project. Pimco bought $10B of the bonds that priced Friday, while other investors bought the remaining debt, people with knowledge of the matter told Bloomberg. 4) NeuroSense (NRSN) announced on Friday that Dr. Ferenc Tracik will step down from his role as the company's Chief Medical Officer, effective April 27. Tracik will continue to support the company as an independent advisor, NeuroSense added. "Dr. Tracik's departure is not the result of any disagreement with the Company on matters relating to its operations, policies, or practices," it said. 5) Medtronic (MDT) announced the U.S. Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of VT, providing an expedited regulatory pathway for the technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 13.420
Low
5.00
Averages
8.50
High
12.00
Current: 13.420
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investors' Rights Investigation and Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Open Lending Corporation (NASDAQ: LPRO) for its sale to ANV Group Holdings Ltd. at $3.15 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Cash Acquisition Concerns: Nuvalent, Inc. (NASDAQ: NUVL) is being sold to GSK plc for $124.00 per share in cash, and Halper Sadeh LLC encourages shareholders to be aware of potential compromised rights and to proactively seek legal support.
- Merger Transaction Review: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek to negotiate a higher transaction price and additional disclosures to protect shareholder interests.
- Impact of SUNation Merger: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to give SUNation shareholders approximately 1.8% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking better transaction terms and rights protection.
See More
Organon Receives FDA Approval for TOFIDENCE New Indications
- FDA Approval for New Indications: Organon announced that its TOFIDENCE (tocilizumab-bavi) injection received FDA approval, expanding its indications to treat severe cytokine release syndrome (CRS) in patients aged 2 and older and hospitalized COVID-19 patients, marking a significant advancement in the biosimilars sector.
- Market Potential Expansion: As the first approved tocilizumab biosimilar in the US, TOFIDENCE is expected to enhance patient access by reducing the financial burden of high-cost brand biologics, thereby strengthening Organon's competitive position in the biopharmaceutical market.
- Multiple Indication Coverage: TOFIDENCE is indicated not only for CRS and COVID-19 but also for rheumatoid arthritis and giant cell arteritis, showcasing its broad clinical application potential and further solidifying Organon's product portfolio.
- Safety Considerations: Patients treated with TOFIDENCE face risks of serious infections, including tuberculosis; Organon emphasizes the need for close monitoring of infection symptoms during treatment to ensure patient safety and optimize therapeutic outcomes.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Nuvalent, Inc. (NASDAQ: NUVL) regarding its sale to GSK plc for $124.00 per share in cash, potentially infringing on shareholder rights.
- Merger Transaction Review: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to result in SUNation shareholders owning approximately 1.8% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Shareholder Rights Protection: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, with Halper Sadeh LLC encouraging Organon shareholders to understand their legal rights.
- Cash Acquisition Focus: Taylor Morrison Home Corporation (NYSE: TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per share in cash, and Halper Sadeh LLC will represent shareholders in seeking additional disclosures and compensation.
See More
Investor Alert: Investigations into Multiple Mergers
- Nuvalent Acquisition Investigation: Nuvalent, Inc. is set to be acquired by GSK plc for $124.00 per share in a cash deal valued at $10.6 billion, with investigations focusing on whether the Nuvalent Board breached fiduciary duties by failing to ensure a fair process for shareholders.
- SUNation Energy Merger Concerns: SUNation Energy will merge with Suniva, resulting in pre-merger SUNation shareholders holding only approximately 1.8% of the combined entity, raising questions about the Board's adherence to fiduciary responsibilities and the fairness of the transaction.
- Organon Acquisition Scrutiny: Organon & Co. is being acquired by Sun Pharmaceutical Industries for $14.00 per share in an all-cash transaction valued at $11.75 billion, with investigations examining whether the Board failed to conduct a fair process, potentially impacting shareholder value.
- Taylor Morrison Merger Investigation: Taylor Morrison Home Corporation will be acquired by Berkshire Hathaway for $72.50 per share, representing an equity value of approximately $6.8 billion, with investigations questioning the Board's fiduciary duties and the fairness of the proposed transaction.
See More
Pharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
- Accelerated Acquisition Activity: In 2026, global biopharma M&A deal value reached $106 billion across 201 transactions, reflecting a strong acquisition appetite among pharmaceutical companies facing patent expirations, with projections suggesting total deal value could exceed $250 billion for the year, marking the sector's best performance since the pre-pandemic peak in 2019.
- Increasing Deal Sizes: The average deal size has climbed to $527.3 million in 2026, up from $365 million in 2025, indicating that pharmaceutical firms are focusing on acquiring high-value assets to enhance their product portfolios and competitive positioning in the market.
- Strategic Acquisition Preferences: Companies are shifting towards strategic “bolt-on” acquisitions in the $1 billion to $5 billion range rather than large leveraged buyouts or mega-mergers, enabling them to quickly supplement near-commercial products while also investing in early-stage assets to access innovative technologies.
- Major Deal Examples: The five largest M&A transactions in 2026 include Sun Pharmaceutical's $11.75 billion acquisition of Organon, Gilead's $7.8 billion purchase of Arcellx, Merck's $6.7 billion acquisition of Terns, Eli Lilly's $7.8 billion deal for Centessa, and Biogen's $5.6 billion acquisition of Apellis, highlighting the industry's consolidation trend and demand for new technologies.
See More
Organon to Present New Research Findings at ISPOR 2026
- Research Presentation: Organon will showcase eight abstracts at ISPOR 2026, taking place from May 17-20 in Philadelphia, focusing on women's health, biosimilars, and neurology, highlighting its commitment to health economics and outcomes research aimed at improving patient health outcomes.
- Budget Impact Analysis: The analysis of NEXPLANON®'s cost-effectiveness and budget impact in Brazil will incorporate real-world utilization data and private payer perspectives, aiming to provide empirical support for healthcare decision-making and enhance market acceptance of the product.
- Biosimilar Adoption Study: Organon will present a budget impact analysis of POHERDY® for HER2-positive breast cancer treatment and a real-world budget impact analysis of biosimilar adoption in a mid-sized Brazilian health maintenance organization, aiming to drive market penetration of biosimilars.
- Patient Pathway Research: The exploration of real-world referral patterns and healthcare utilization among headache patients in the UK will contribute to a better understanding of patient pathways and healthcare resource use, providing data support for improving patient care in the neurology field.
See More
Investors' Rights Investigation and Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Open Lending Corporation (NASDAQ: LPRO) for its sale to ANV Group Holdings Ltd. at $3.15 per share, which may infringe on shareholder rights, prompting shareholders to understand their rights and options.
- Cash Acquisition Concerns: Nuvalent, Inc. (NASDAQ: NUVL) is being sold to GSK plc for $124.00 per share in cash, and Halper Sadeh LLC encourages shareholders to be aware of potential compromised rights and to proactively seek legal support.
- Merger Transaction Review: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, and Halper Sadeh LLC may seek to negotiate a higher transaction price and additional disclosures to protect shareholder interests.
- Impact of SUNation Merger: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to give SUNation shareholders approximately 1.8% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking better transaction terms and rights protection.
See More
Organon Receives FDA Approval for TOFIDENCE New Indications
- FDA Approval for New Indications: Organon announced that its TOFIDENCE (tocilizumab-bavi) injection received FDA approval, expanding its indications to treat severe cytokine release syndrome (CRS) in patients aged 2 and older and hospitalized COVID-19 patients, marking a significant advancement in the biosimilars sector.
- Market Potential Expansion: As the first approved tocilizumab biosimilar in the US, TOFIDENCE is expected to enhance patient access by reducing the financial burden of high-cost brand biologics, thereby strengthening Organon's competitive position in the biopharmaceutical market.
- Multiple Indication Coverage: TOFIDENCE is indicated not only for CRS and COVID-19 but also for rheumatoid arthritis and giant cell arteritis, showcasing its broad clinical application potential and further solidifying Organon's product portfolio.
- Safety Considerations: Patients treated with TOFIDENCE face risks of serious infections, including tuberculosis; Organon emphasizes the need for close monitoring of infection symptoms during treatment to ensure patient safety and optimize therapeutic outcomes.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Nuvalent, Inc. (NASDAQ: NUVL) regarding its sale to GSK plc for $124.00 per share in cash, potentially infringing on shareholder rights.
- Merger Transaction Review: SUNation Energy, Inc. (NASDAQ: SUNE) is merging with Suniva, which is expected to result in SUNation shareholders owning approximately 1.8% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Shareholder Rights Protection: Organon & Co. (NYSE: OGN) is selling to Sun Pharmaceutical Industries Limited for $14.00 per share, with Halper Sadeh LLC encouraging Organon shareholders to understand their legal rights.
- Cash Acquisition Focus: Taylor Morrison Home Corporation (NYSE: TMHC) is being sold to Berkshire Hathaway Inc. for $72.50 per share in cash, and Halper Sadeh LLC will represent shareholders in seeking additional disclosures and compensation.
See More
Investor Alert: Investigations into Multiple Mergers
- Nuvalent Acquisition Investigation: Nuvalent, Inc. is set to be acquired by GSK plc for $124.00 per share in a cash deal valued at $10.6 billion, with investigations focusing on whether the Nuvalent Board breached fiduciary duties by failing to ensure a fair process for shareholders.
- SUNation Energy Merger Concerns: SUNation Energy will merge with Suniva, resulting in pre-merger SUNation shareholders holding only approximately 1.8% of the combined entity, raising questions about the Board's adherence to fiduciary responsibilities and the fairness of the transaction.
- Organon Acquisition Scrutiny: Organon & Co. is being acquired by Sun Pharmaceutical Industries for $14.00 per share in an all-cash transaction valued at $11.75 billion, with investigations examining whether the Board failed to conduct a fair process, potentially impacting shareholder value.
- Taylor Morrison Merger Investigation: Taylor Morrison Home Corporation will be acquired by Berkshire Hathaway for $72.50 per share, representing an equity value of approximately $6.8 billion, with investigations questioning the Board's fiduciary duties and the fairness of the proposed transaction.
See More
Pharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs
- Accelerated Acquisition Activity: In 2026, global biopharma M&A deal value reached $106 billion across 201 transactions, reflecting a strong acquisition appetite among pharmaceutical companies facing patent expirations, with projections suggesting total deal value could exceed $250 billion for the year, marking the sector's best performance since the pre-pandemic peak in 2019.
- Increasing Deal Sizes: The average deal size has climbed to $527.3 million in 2026, up from $365 million in 2025, indicating that pharmaceutical firms are focusing on acquiring high-value assets to enhance their product portfolios and competitive positioning in the market.
- Strategic Acquisition Preferences: Companies are shifting towards strategic “bolt-on” acquisitions in the $1 billion to $5 billion range rather than large leveraged buyouts or mega-mergers, enabling them to quickly supplement near-commercial products while also investing in early-stage assets to access innovative technologies.
- Major Deal Examples: The five largest M&A transactions in 2026 include Sun Pharmaceutical's $11.75 billion acquisition of Organon, Gilead's $7.8 billion purchase of Arcellx, Merck's $6.7 billion acquisition of Terns, Eli Lilly's $7.8 billion deal for Centessa, and Biogen's $5.6 billion acquisition of Apellis, highlighting the industry's consolidation trend and demand for new technologies.
See More
Organon to Present New Research Findings at ISPOR 2026
- Research Presentation: Organon will showcase eight abstracts at ISPOR 2026, taking place from May 17-20 in Philadelphia, focusing on women's health, biosimilars, and neurology, highlighting its commitment to health economics and outcomes research aimed at improving patient health outcomes.
- Budget Impact Analysis: The analysis of NEXPLANON®'s cost-effectiveness and budget impact in Brazil will incorporate real-world utilization data and private payer perspectives, aiming to provide empirical support for healthcare decision-making and enhance market acceptance of the product.
- Biosimilar Adoption Study: Organon will present a budget impact analysis of POHERDY® for HER2-positive breast cancer treatment and a real-world budget impact analysis of biosimilar adoption in a mid-sized Brazilian health maintenance organization, aiming to drive market penetration of biosimilars.
- Patient Pathway Research: The exploration of real-world referral patterns and healthcare utilization among headache patients in the UK will contribute to a better understanding of patient pathways and healthcare resource use, providing data support for improving patient care in the neurology field.
See More
